Du är här

2014-05-26

RECORDATI: RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

Milan, 26 May 2014 -
Recordati announces, following its previous releases dated 24 July 2013 and 31
October 2013, the successful conclusion of the acquisition of a further 23%
of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company
with headquarters in Ariana, near Tunis. This second tranche consists of
share capital held by Tunisian shareholders.

In summary, the two transactions described below relate to the execution of
the agreements signed in July 2013 for the acquisition of 90% of the share
capital of Opalia Pharma S.A..

In October 2013, following permission received from the Tunisian anti-trust
authorities, 67% of the share capital of Opalia Pharma S.A. held by
non-Tunisian shareholders, one of which is The Abraaj Group, was acquired. An
amount of € 22.6 million were paid at the closing.

Today, following permission granted by theCommission Supérieure des
Investissements
in Tunisia, a further 23% of the share capital of Opalia Pharma S.A. held by
Tunisian shareholders was acquired. The price of this portion of shares is of
around € 5.9 million of which around € 4.3 million were paid today.

Following the transactions described above, as of today Recordati holds 90% of
the share capital of Opalia Pharma S.A., while the remaining 10% is held by
Mrs. Alya El Hedda, one of the founders of Opalia Pharma S.A. and current
General Manager of the company.

Opalia Pharma was established in 1988, ranks tenth in the Tunisian
pharmaceutical market and is the third largest local pharmaceutical company.
The company markets branded generic drugs with leading products in
dermatology and in the gastrointestinal and respiratory therapeutic areas.
Opalia manufactures most of its products in a modern, cGMP certified
production facility specialized in liquid and semi-solid forms.

Recordati

, established in 1926, is an international pharmaceutical group, listed on the
Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT
0003828271), with a total staff of around 4,000, dedicated to the research,
development, manufacturing and marketing of pharmaceuticals. Headquartered in
Milan, Italy, Recordati has operations in the main European countries, in
Russia, in other Central and Eastern European countries, in Turkey, in North
Africa and in the United States of America. An efficient field force of
medical representatives promotes a wide range of innovative pharmaceuticals,
both proprietary and under license, in a number of therapeutic areas
including a specialized business dedicated to treatments for rare diseases.
Recordati is a partner of choice for new product licenses for its
territories. Recordati is committed to the research and development of new
specialties within the urogenital therapeutic area and of treatments for rare
diseases. Consolidated revenue for 2013 was € 941.6 million, operating
income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media
Relations
Marianne Tatschke Ketchum

(39)0248787393
Cristina Risciotti, (39)0262411919,cristina.risciotti@ketchum.com

e-mail:inver@recordati.it Marzia
Ongaretti, (39)0262411915,marzia.ongaretti@ketchum.com

S
tatements contained in this release, other than historical facts, are
"forward-looking statements" (as such term is defined in the Private
Securities Litigation Reform Act of 1995). These statements are based on
currently available information, on current best estimates, and on
assumptions believed to be reasonable. This information, these estimates and
assumptions may prove to be incomplete or erroneous, and involve numerous
risks and uncertainties, beyond the Company's control. Hence, actual results
may differ materially from those expressed or implied by such forward-looking
statements. All mentions and descriptions of Recordati products are intended
solely as information on the general nature of the company's activities and
are not intended to indicate the advisability of administering any product in
any particular instance.

RECORDATI FINALIZES 2ND TRANCHE OF ITS ACQUISITION OF OPALIA
http://hugin.info/143644/R/1788508/614473.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RECORDATI via Globenewswire

HUG#1788508

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.